Company / Net Income
Cogent Biosciences, Inc. Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$328.9M
FY2025
5-year range
-$328.9M / -$72.3M
FY2021-FY2025
Trend
-28.6%
vs FY2024
Sector context
#181 of 214
Health Care
What the data says
Cogent Biosciences, Inc.'s net income of -$329M is lower than 85% of companies in the Health Care sector (FY2025). Net Income has declined for 4 consecutive years, from -$72M in FY2021 to -$329M in FY2025.
Based on SEC 10-K filings.
-$329M in FY2025.
Declined from -$192M to -$329M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 214This company -$328.9M Sector average $443.1M
▼
-174.2% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s net income has declined for 4 consecutive years.
- In FY2025, net income decreased 28.6% year-over-year.
- Ranks #181 out of 214 companies in the Health Care sector.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$328.9M | -28.6% |
| FY2024 | -$255.9M | -33.0% |
| FY2023 | -$192.4M | -37.2% |
| FY2022 | -$140.2M | -94.0% |
| FY2021 | -$72.3M | +3.4% |
| FY2020 | -$74.8M | -135.0% |
| FY2019 | -$31.8M | +7.8% |
| FY2018 | -$34.5M | -35.5% |
| FY2017 | -$25.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026